Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 30 September 2024 AM
Janssen's highly anticipated multiple myeloma (MM) treatment Talvey has been provisionally approved by the TGA for heavily pretreated patients.
The first-in-class bispecific GPRC5D-directed CD3 T-cell engager is indicated as a monotherapy for adults with relapsed or refractory MM, who have previously received at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.